Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings has appointed Dr. Phil L’Huillier as its new CEO, effective November 18, 2024, as it prepares to capitalize on its innovative cancer immunotherapy platforms. Dr. L’Huillier, with a robust background in advancing cancer therapeutics and successful fundraising, joins the company at a critical point as Scancell targets late-stage clinical trials. Professor Lindy Durrant will continue as Chief Scientific Officer, focusing on advancing the company’s promising vaccine and antibody platforms.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
